Glenmark Pharmaceuticals has come out with positive findings from phase 2a study of GBR 830, an investigational monoclonal anti-body in atopic dermatitis, a chronic skin disease. It now plans to initiate a phase 2b trial in the first half of 2018.
“The study evaluated the safety, biological and clinical activity, and pharmacokinetics of GBR 830, relative to placebo, in adults with moderate-to-severe AD with history of inadequate response to topical therapies,” Glenmark Pharma said in a BSE filing today.
The company further said: “Based on the results of this Phase 2a study, Glenmark is firmly committed to advancing GBR 830 for patients with AD and plans to initiate a phase 2b trial in the first half of calendar year 2018.”
Glenmark Pharma President and Chief Medical Officer Fred Grossman said atopic dermatitis can have a severe impact on the quality of life and there is an unmet need for safe and more durable therapies for people suffering from the disease. In the Phase 2a study, about 31 patients were evaluated.